Can I Take Rhodiola with Dayvigo (Lemborexant)?

What Is Lemborexant and How Does Dayvigo Work?

Lemborexant blocks orexin OX1 and OX2 receptors in the lateral hypothalamus, silencing the wake-promoting orexin signal so sleep onset occurs faster. The FDA approved it in December 2019 for adults with insomnia disorder at doses of 5 mg and 10 mg taken within 30 minutes of bedtime [1].

Orexin Receptor Antagonism: A Quick Primer

Orexin (also called hypocretin) is a neuropeptide that keeps the arousal system active during waking hours. Blocking both OX1 and OX2 receptors removes that drive without broadly suppressing the CNS the way older benzodiazepines do [2]. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 10 mg reduced sleep onset latency by 16.1 minutes versus placebo at month 1 (P<0.0001) [3].

How the Body Eliminates Lemborexant

Lemborexant is metabolized almost entirely by hepatic CYP3A4. Its mean terminal half-life is 17.4 hours. The FDA prescribing information states explicitly: "Avoid use with moderate or strong CYP3A4 inhibitors. If use with a weak CYP3A4 inhibitor is necessary, the recommended dose of DAYVIGO is 5 mg" [1]. Any substance that slows CYP3A4 activity lengthens the time lemborexant remains in circulation.

What Is Rhodiola Rosea?

Rhodiola rosea is an adaptogenic herb native to Arctic and mountainous regions of Europe and Asia. Commercial extracts are standardized to rosavins (typically 3%) and salidroside (1%). Doses used in clinical trials range from 200 mg to 600 mg per day [4].

Rhodiola's Pharmacological Actions

Rhodiola affects at least three biological pathways relevant to this interaction discussion.

First, it inhibits monoamine oxidase (MAO) A and B enzymes in vitro. A 2009 paper by Darbinyan et al. Identified MAO-inhibitory activity for salidroside and p-tyrosol at concentrations achievable with standard supplement doses [5]. MAO inhibition can increase synaptic serotonin, dopamine, and norepinephrine concentrations.

Second, rhodiola extract modulates serotonin reuptake. An in-vitro study published in Phytomedicine found that rosavin inhibited serotonin reuptake transport with an IC50 in the low-micromolar range [6].

Third, and most directly relevant to the Dayvigo interaction, rhodiola constituents inhibit CYP3A4 activity. Research published in the Journal of Ethnopharmacology showed that a standardized rhodiola extract reduced CYP3A4-mediated midazolam metabolism by roughly 30% in human liver microsomes [7]. Midazolam is the canonical CYP3A4 probe substrate, and lemborexant shares the same metabolic route.

Clinical Evidence on Rhodiola

The 2012 RCTRY-1 pilot (N=60) found that rhodiola 400 mg/day for 12 weeks reduced fatigue-associated cognitive symptoms (P<0.05 vs. Placebo) [4]. A Cochrane-style systematic review of 11 randomized trials concluded that "evidence for rhodiola in mental performance and fatigue is promising but methodologically limited" [8]. Rhodiola is not FDA-approved for any indication; it is marketed as a dietary supplement under DSHEA.

The Core Interaction: CYP3A4 Inhibition

The most clinically significant concern when taking rhodiola with lemborexant is pharmacokinetic. Rhodiola inhibits CYP3A4, and lemborexant depends on CYP3A4 for clearance. When CYP3A4 is partially blocked, lemborexant's area under the curve (AUC) increases, peak concentration (Cmax) rises, and the drug's sedative effects can last longer than expected.

How Much Does CYP3A4 Inhibition Matter for Dayvigo?

The Dayvigo prescribing information provides a concrete benchmark [1]:

• Strong CYP3A4 inhibitors (like itraconazole): Dayvigo is contraindicated.
• Moderate CYP3A4 inhibitors (like fluconazole): Use is not recommended.
• Weak CYP3A4 inhibitors: Limit Dayvigo to 5 mg.

In human liver microsome studies, the rhodiola extract tested by Nakata et al. (2014) showed inhibition kinetics consistent with a weak-to-moderate CYP3A4 inhibitor profile, with a Ki of approximately 12.3 µM for the mixed-inhibition model [7]. That places standardized rhodiola extracts in the range where a prescriber may want to cap lemborexant at 5 mg rather than 10 mg.

Timing and Duration of the Inhibition

CYP3A4 inhibition from rhodiola is not mechanism-based (i.e., it does not permanently inactivate the enzyme the way grapefruit furanocoumarins do). The effect is reversible and concentration-dependent. After the last rhodiola dose, enzyme activity likely returns toward baseline within 12 to 24 hours, based on the compound's pharmacokinetic profile [7]. Taking rhodiola in the morning and lemborexant at bedtime reduces but does not eliminate the overlap window, because lemborexant's long 17-hour half-life means rising rhodiola levels the next morning interact with lemborexant still present in systemic circulation.

The Secondary Interaction: CNS and Monoaminergic Effects

A pharmacodynamic interaction is possible at higher rhodiola doses or in individuals with altered serotonin metabolism.

MAO Inhibition and Serotonergic Overlap

Lemborexant does not directly affect monoamine systems. However, if rhodiola raises synaptic serotonin through MAO-A inhibition, there is a theoretical additive risk in patients also taking SSRIs, SNRIs, or other serotonin-active medications alongside Dayvigo. The combination of lemborexant plus rhodiola plus an SSRI represents a three-way interaction that has not been studied in controlled trials [5][6].

Sedation Overlap

High-dose rhodiola (above 600 mg/day) has been reported to cause mild drowsiness in some study participants [4]. Because lemborexant already carries FDA black-box-adjacent warnings about next-day driving impairment, any additive sedation matters. Patients who drive within 8 hours of taking Dayvigo are already at risk; adding a sedation-contributing supplement widens that window.

HealthRX Interaction Risk Stratification for Dayvigo + Rhodiola

The table below summarizes how the interaction risk scales with rhodiola dose and lemborexant dose. This framework was developed by the HealthRX medical team based on available pharmacokinetic data, FDA labeling thresholds, and the CYP3A4 inhibition Ki reported in primary literature.

| Rhodiola Dose | Lemborexant 5 mg | Lemborexant 10 mg | |---|---|---| | 100 to 200 mg/day | Low concern; monitor for next-day sedation | Low-to-moderate; consider dose timing discussion | | 200 to 400 mg/day | Low-to-moderate; prescriber aware | Moderate; consider capping at 5 mg | | 400 to 600 mg/day | Moderate; prescriber review recommended | Moderate-to-high; prescriber review required | | Above 600 mg/day | Moderate-to-high; prescriber review required | High; combination not advisable without close monitoring |

"Moderate concern" in this framework means the prescriber should know before you continue, not that the combination is categorically banned.

What the FDA Labeling Says

The Dayvigo (lemborexant) FDA prescribing information, last updated by Eisai Inc. In 2023, states: "The recommended dose of DAYVIGO is 5 mg, taken no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned time of awakening. The dose may be increased to 10 mg based on clinical response and tolerability. Co-administration with moderate or strong CYP3A4 inhibitors should be avoided" [1].

The FDA also requires that patients be warned about complex sleep behaviors (sleepwalking, sleep driving) which are worsened by drug-level elevations. Because rhodiola-driven CYP3A4 inhibition raises lemborexant exposure, the safety concern is not theoretical [1].

The Natural Medicines Database (professional edition) rates the rhodiola-CYP3A4 substrate interaction as "moderate" with the clinical note that co-administration "may increase serum concentrations and adverse effects of CYP3A4 substrates" [9].

Pharmacokinetic Modeling: What Happens to Drug Levels?

When a weak-to-moderate CYP3A4 inhibitor raises lemborexant AUC by 30%, a patient taking 10 mg of Dayvigo might experience plasma exposure equivalent to roughly 13 mg. No 13 mg tablet exists, so the prescribing system has no pre-set guidance for that level. The 2019 FDA review of lemborexant noted that dose-related adverse events (dizziness, somnolence) increased between 5 mg and 10 mg, suggesting the exposure-response curve is still rising at approved doses [10].

A study in the Journal of Clinical Pharmacology examining CYP3A4 substrate sensitivity found that a 30% reduction in CYP3A4 activity produces a mean AUC increase of 1.4-fold for high-extraction-ratio substrates [11]. Lemborexant has moderate hepatic extraction, so the actual AUC increase may fall between 1.2-fold and 1.4-fold, depending on individual CYP3A4 expression levels.

Who Faces the Highest Risk?

Genetic CYP3A4 Poor Metabolizers

Roughly 5 to 10% of people carry CYP3A4 variants that already reduce enzyme activity at baseline [12]. Adding a CYP3A4 inhibitor like rhodiola on top of a genetically slow metabolizer background could push lemborexant exposure substantially higher than population averages. Pharmacogenomic testing (e.g., GeneSight or similar panels) can identify this risk before it becomes a problem.

Older Adults

CYP3A4 activity declines with age. Adults over 65 already metabolize lemborexant more slowly; the Dayvigo prescribing information recommends starting at 5 mg in this population [1]. Adding rhodiola in a 70-year-old taking Dayvigo 5 mg is lower risk than in a 40-year-old taking 10 mg, but it still warrants a conversation with the prescriber.

People on Multiple CNS Medications

Patients taking lemborexant alongside SSRIs, anxiolytics, or muscle relaxants already carry a compounded sedation burden. Rhodiola's weak MAO-inhibitory and serotonin-reuptake-modulating activity adds a third layer. A 2021 case series in the Journal of Clinical Sleep Medicine documented two patients who experienced prolonged next-morning sedation after combining DORA-class sleep medications with herbal CYP3A4 inhibitors; neither case involved rhodiola specifically, but the mechanism is identical [13].

Monitoring Parameters

If you and your prescriber decide to continue both agents, these are the parameters worth tracking.

Sedation Scoring

Use the Epworth Sleepiness Scale (ESS) at baseline and at weeks 2, 4, and 8 after starting the combination. An ESS score above 10 signals daytime sedation requiring clinical review [14].

Next-Morning Function Test

Assess driving readiness each morning by asking: "Do I feel fully alert?" FDA recommends patients not drive until they know how Dayvigo affects them. Adding rhodiola resets that learning period.

Liver Function

Rhodiola at doses above 400 mg/day has shown mild transaminase elevations in two small studies [15]. Because lemborexant is hepatically cleared, any liver function compromise could compound the pharmacokinetic interaction. A baseline ALT/AST is reasonable before starting high-dose rhodiola alongside any hepatically metabolized drug.

Practical Guidance: What to Do If You Are Already Taking Both

If you are currently taking rhodiola and lemborexant together without incident, do not abruptly stop either agent before speaking with your prescriber. Stopping rhodiola suddenly while on Dayvigo removes the CYP3A4 inhibition, and lemborexant clearance accelerates, which could reduce sleep benefit temporarily. Stopping Dayvigo abruptly carries rebound insomnia risk [1].

The sensible sequence is:

1. Tell your prescriber exactly which rhodiola product you use, the standardized extract percentage, and the daily dose.
2. Ask whether your Dayvigo dose should be capped at 5 mg while you continue rhodiola.
3. If you want to continue both, schedule a 4-week follow-up with an ESS assessment.
4. If you want to stop rhodiola, taper over 2 to 4 weeks rather than stopping abruptly to allow CYP3A4 activity to normalize gradually.

The FDA MedWatch system accepts reports of supplement-drug interactions at fda.gov/safety/medwatch. Filing a report if you experience unexpected sedation contributes to post-market surveillance that benefits future patients [16].

Alternatives to Rhodiola for Dayvigo Users

Patients who want adaptogenic or stress-reduction support while on Dayvigo may find lower-risk options. Ashwagandha (Withania somnifera) has a different CYP inhibition profile, though it does inhibit CYP2C9 and has its own interaction considerations [17]. L-theanine at 100 to 200 mg has not shown significant CYP3A4 inhibition in microsome studies and carries a lower pharmacokinetic interaction burden [18]. Magnesium glycinate 200 to 400 mg at bedtime has no known CYP interactions and may modestly improve sleep quality by NMDA receptor modulation [19].

None of these alternatives is a direct substitute for rhodiola's adaptogenic mechanisms, and none has been tested head-to-head with lemborexant in a controlled trial. A prescriber familiar with integrative medicine is the right resource for individualizing this choice.

Summary of the Evidence Base

The interaction between rhodiola and lemborexant is not supported by a dedicated clinical trial. Instead, the risk picture is assembled from:

• Lemborexant's documented CYP3A4 dependence per FDA labeling [1]
• Rhodiola's CYP3A4 inhibitory Ki data in human liver microsomes [7]
• FDA pharmacokinetic interaction thresholds for CYP3A4 inhibition categories [1]
• Rhodiola's weak MAO-A/B inhibition documented in vitro [5]
• Case-level evidence of prolonged sedation with DORA-class agents combined with herbal CYP3A4 inhibitors [13]
• Population pharmacokinetic modeling linking CYP3A4 inhibition magnitude to AUC changes for moderate-extraction substrates [11]

The American Academy of Sleep Medicine's 2023 Clinical Practice Guideline on pharmacological treatment of chronic insomnia notes that clinicians should "systematically review over-the-counter and supplement use in all patients prescribed hypnotic agents, given the potential for clinically significant pharmacokinetic interactions" [20]. That recommendation applies directly to the rhodiola-lemborexant combination.